Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Profit After Tax: 2016-2025

Historic Profit After Tax for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$50.3 million.

  • Rocket Pharmaceuticals' Profit After Tax rose 24.56% to -$50.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$240.9 million, marking a year-over-year increase of 6.65%. This contributed to the annual value of -$258.7 million for FY2024, which is 5.35% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Profit After Tax of -$50.3 million as of Q3 2025, which was up 26.97% from -$68.9 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Profit After Tax's 5-year high stood at -$34.5 million during Q2 2021, with a 5-year trough of -$69.6 million in Q2 2024.
  • Its 3-year average for Profit After Tax is -$62.3 million, with a median of -$61.9 million in 2023.
  • The largest annual percentage gain for Rocket Pharmaceuticals' Profit After Tax in the last 5 years was 27.36% (2021), contrasted with its biggest fall of 72.35% (2021).
  • Over the past 5 years, Rocket Pharmaceuticals' Profit After Tax (Quarterly) stood at -$44.2 million in 2021, then slumped by 50.80% to -$66.7 million in 2022, then climbed by 10.59% to -$59.7 million in 2023, then decreased by 1.12% to -$60.3 million in 2024, then rose by 24.56% to -$50.3 million in 2025.
  • Its last three reported values are -$50.3 million in Q3 2025, -$68.9 million for Q2 2025, and -$61.3 million during Q1 2025.